This agreement aims to benefit from GlaxoSmithKline Consumer Healthcare experiences in the consumer health care sector and ensure the transfer of technology for the Consumer Healthcare products to the Kingdom of Saudi Arabia, followed by the commercial-scale production in AJA Pharma manufacturing site. The contractual agreement is for 5 years with an expected revenue of around SAR 100 Mn, driving an increase the production capacity, and thereby expected to result in creating more employment opportunities for Saudis.

Commenting on the agreement, Eng. Thamer Al-Muhid, Group Chief Executive Officer of (SCCH), said that this strategic collaboration would contribute to localisation's national objective. He further emphasised that AJA Pharma aims to provide high-quality pharmaceutical products for the Global Pharma companies operating in the region. “Our mission is to be the partner of choice!” said the GCEO.

About AJA Pharma: AJA Pharmaceutical Industries Company Limited is a subsidiary of Saudi Chemical Company Holding. The Holding company is listed in the Saudi Stock Exchange, Tadawul. AJA Pharma has a Pharmaceutical Manufacturing site in Ha’il, Saudi Arabia.

About GSK : GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.